You are currently viewing our desktop site, do you want to visit our Mobile web app instead?
 Registered users can save articles to their personal articles list. Login here or sign up here

Market for HIV prevention drugs may more than double, Citi says

Sales for HIV prevention drugs could increase to $5.5bn by 2030 from $2bn, currently.

Even with approval approaching for a generic of the first medicine to prevent HIV, the US market for similar medicines may more than double by 2030, a Citi analyst predicts.

Sales for HIV prevention drugs could increase to $5.5 billion by 2030 from a current total of $2 billion, despite the 2020 entry of a generic of Gilead Sciences’ Truvada, analyst Citi Andrew Baum wrote in a client note.

Truvada, which is also used to treat HIV, generated $3 billion of sales in 2018, and has faced congressional scrutiny over its cost.

An experimental drug from Merck & Co may lead the way in the US market, Citi said. Baum estimates MK-8591 may reach sales of $7 billion in HIV. Of that total, $3.5 billion may come from pre-exposure prophylaxis, or PrEP, as the preventative treatments are called.

While Citi prefers Merck as well as European peers AstraZeneca, Novartis, Sanofi and Bayer in the PrEP market, it is also keeping an eye on a new Gilead medicine in development. Results for GS-6207 may be presented at a scientific meeting, the IAS Conference on HIV Science later this month in Mexico City.

© 2019 Bloomberg L.P.

Get access to Moneyweb's financial intelligence and support quality journalism for only
R63/month or R630/year.
Sign up here, cancel at any time.

COMMENTS   0

To comment, you must be registered and logged in.

LOGIN HERE

Don't have an account?
Sign up for FREE

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR

Podcasts

NEWSLETTERS WEB APP SHOP PORTFOLIO TOOL TRENDING CPD HUB

Follow us:

Search Articles:Advanced Search
Click a Company: